Denali Therapeutics, Inc.

As of October 3, 2025, Denali Therapeutics, Inc. shows a mildly bearish trend influenced by daily moving averages, while underperforming the S&P 500 with a year-to-date return of -24.34% compared to the index's 14.18%.

As of October 3, 2025, Denali Therapeutics, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly indicators suggest mild bullishness, and the stock has significantly underperformed the S&P 500 with year-to-date and one-year returns of -24.34% and -45.36%, respectively.

As of September 12, 2025, Denali Therapeutics, Inc. has a bearish trend with weak strength, indicated by negative daily moving averages and monthly MACD, despite some mildly bullish signals on the weekly indicators, and it has significantly underperformed the S&P 500 with year-to-date and one-year returns of -35.33% and -57.15%, respectively.

As of November 6, 2024, Denali Therapeutics, Inc. is overvalued and has deteriorated to a "does not qualify" rating due to negative financial metrics and a year-to-date return of -33.17%, significantly underperforming compared to its peers and the S&P 500.

As of June 2, 2025, the market trend is mildly bearish, with mixed signals from various indicators, including a bearish monthly MACD and daily moving averages, suggesting a cautious approach.

As of March 2022, Denali Therapeutics, Inc.'s management team includes Dr. Vicki Sato (Independent Chairman), Mr. Ryan Watts (President and CEO), and several independent directors: Ms. Nancy Thornberry, Mr. Douglas Cole, Ms. Jennifer Cook, Mr. Jay Flatley, and Mr. Peter Klein. They oversee the company's strategic direction and operations.

Denali Therapeutics, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases, with a market cap of approximately $2.04 billion and a recent net profit of -$133 million. The company has no dividend yield and is currently loss-making.

As of Jun 18, Denali Therapeutics, Inc. has a market capitalization of $2,035.32 million, with net sales of $0.00 million and a net profit of -$453.94 million over the latest four quarters. The company reported shareholder's funds of $1,229.68 million and total assets of $1,374.18 million as of Dec'24.